Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Not yet recruiting 2

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Specimen Handling 17Biopsy 9Magnetic Resonance Spectroscopy 8X-Rays 5Cyclophosphamide 5venetoclax 4fludarabine 4dexamethasone acetate 4dexamethasone 21-phosphate 4auricularum 4Dexamethasone 4Calcium Dobesilate 4carfilzomib 3Hyaluronoglucosaminidase 3sargramostim 2pomalidomide 2decitabine and cedazuridine drug combination 2daratumumab 2balstilimab 2Whole-Body Irradiation 2Stem Cell Transplantation 2Photons 2Melphalan 2Fluorodeoxyglucose F18 2Doxorubicin 2Cytarabine 2Colony-Stimulating Factors 2Busulfan 2trastuzumab deruxtecan 1sacituzumab govitecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × NIH × balstilimab × Clear all
NCT07516366 2026-05-15

Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial

National Cancer Institute (NCI)

Phase 2 Not yet recruiting
16 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT07551596 2026-05-15

Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial

National Cancer Institute (NCI)

Phase 2 Not yet recruiting
20 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡